Nicox Reports Findings from Whistler Phase 3b Glaucoma Trial

Nicox has disclosed findings from its Whistler Phase 3b exploratory trial, examining the dual action of NCX 470, a treatment for reducing intraocular pressure (IOP) in glaucoma. The trial highlighted significant results in several nitric oxide-stimulated aqueous humor parameters, although changes in episcleral venous pressure were not considerable compared to placebo.

Conducted on 18 participants, the study observed significant changes in aqueous humor dynamics due to nitric oxide's impact on the trabecular meshwork. These promising results could lead to further exploration of NCX 470's dual mechanism involving nitric oxide and prostaglandin pathways.

The safety profile of NCX 470 remains consistent with previous studies. Importantly, these findings will not affect the timeline for New Drug Application submissions, as the trial was primarily exploratory.